ANTHRACYCLINE-INDUCED CARDIAC TOXICITY
Clinical trials for ANTHRACYCLINE-INDUCED CARDIAC TOXICITY explained in plain language.
Never miss a new study
Get alerted when new ANTHRACYCLINE-INDUCED CARDIAC TOXICITY trials appear
Sign up with your email to follow new studies for ANTHRACYCLINE-INDUCED CARDIAC TOXICITY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Simple cuff trick may shield hearts from chemo damage
Disease control Recruiting nowThis study tests whether temporarily stopping blood flow in the arm with a blood pressure cuff can protect the hearts of lymphoma patients receiving chemotherapy. The procedure, called remote ischemic preconditioning, is done before each chemo session. Researchers will compare he…
Matched conditions: ANTHRACYCLINE-INDUCED CARDIAC TOXICITY
Phase: NA • Sponsor: Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III • Aim: Disease control
Last updated Jun 26, 2026 18:39 UTC
-
Heart shield? diabetes drug tested to prevent chemo heart damage
Prevention Recruiting nowThis study tests whether dapagliflozin, a drug used for diabetes and heart failure, can prevent heart damage caused by a common type of chemotherapy (anthracyclines) in breast cancer patients. One hundred women will receive either dapagliflozin or a placebo daily during their che…
Matched conditions: ANTHRACYCLINE-INDUCED CARDIAC TOXICITY
Phase: PHASE2 • Sponsor: University Medical Centre Ljubljana • Aim: Prevention
Last updated Jun 27, 2026 07:59 UTC